<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902184</url>
  </required_header>
  <id_info>
    <org_study_id>IPH4102-201</org_study_id>
    <secondary_id>2018-003969-33</secondary_id>
    <nct_id>NCT03902184</nct_id>
  </id_info>
  <brief_title>IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma</brief_title>
  <acronym>TELLOMAK</acronym>
  <official_title>TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-cohort, and multi-center phase II study, which evaluates the&#xD;
      clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single&#xD;
      agent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Using the Olsen (2011, JCO) criteria (All cohorts)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (All cohorts)</measure>
    <time_frame>From first dose until study completion, an expected average of 2 years</time_frame>
    <description>patients with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) (All cohorts)</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>Using the Skindex29 questionnaire to assesse the effects of skin disease on quality of life in three domains: Symptoms, Emotions, and Functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pruritus (All cohorts)</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>Using Visual Analog Scale (VAS) for prutitus assessment: From 0 = No pruritus to 10 = Pruritus as bad as it could possibly be</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR using blinded central review (Cohort 1)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Using the Olsen (2011, JCO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) (All cohorts)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (All cohorts)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters : Maximum Plasma Concentration of IPH4102 alone (All cohorts)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Maximum Plasma Concentration (Cmax) (W1, W5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters :Trough Concentration of IPH4102 alone (All cohorts)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>Trough Concentration (Ctrough) every 8 or 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of IPH4102 alone (All cohorts)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
    <description>A serum sample will be collected at the specified time points for evaluation of anti-drug antibodies (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first dose until study completion, an expected average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Lymphoma, T-Cell</condition>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <condition>Mycosis Fungoides/Sezary Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Relapsed/refractory Sezary Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPH4102</intervention_name>
    <description>Patients will receive a flat dose of 750mg</description>
    <arm_group_label>Cohort 1: Relapsed/refractory Sezary Syndrome</arm_group_label>
    <arm_group_label>Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing</arm_group_label>
    <arm_group_label>Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing</arm_group_label>
    <other_name>lacutamab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Patients must meet all of the inclusion criteria in order to be eligible to participate in&#xD;
        the study.&#xD;
&#xD;
        Cohort 1:&#xD;
&#xD;
          1. Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior&#xD;
             systemic therapies;&#xD;
&#xD;
          2. Prior treatment with mogamulizumab;&#xD;
&#xD;
          3. Patients should have blood stage B2 at screening based on central evaluation by flow&#xD;
             cytometry;&#xD;
&#xD;
          4. Feasibility of obtaining at least one skin biopsy at screening;&#xD;
&#xD;
             Cohorts 2 and 3:&#xD;
&#xD;
          5. Relapsed and/or refractory stage IB, IIA, IIB, III, IV MF;&#xD;
&#xD;
          6. KIR3DL2 expression (Cohort 2) or non-expression (Cohort 3) in at least one skin lesion&#xD;
             based on central evaluation by IHC;&#xD;
&#xD;
          7. Patients should have received at least two prior systemic therapies;&#xD;
&#xD;
          8. Feasibility of obtaining at least one skin biopsy at screening;&#xD;
&#xD;
             Additional inclusion criteria applicable to all cohorts:&#xD;
&#xD;
          9. Male or Female, at least 18 years of age;&#xD;
&#xD;
         10. ECOG performance status ≤2;&#xD;
&#xD;
         11. The patient must have a minimum wash-out period of 3 weeks between the last dose of&#xD;
             prior systemic therapy and the first dose of IPH4102;&#xD;
&#xD;
         12. Patients should have recovered from all non-hematological adverse events related to&#xD;
             prior therapy to ≤ grade 1 except for alopecia;&#xD;
&#xD;
         13. Adequate baseline laboratory data:&#xD;
&#xD;
             Hematology:&#xD;
&#xD;
               -  Hemoglobin &gt;9 g/dL,&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1,500/µL,&#xD;
&#xD;
               -  Platelets ≥100,000/µL,&#xD;
&#xD;
             Biochemistry:&#xD;
&#xD;
               -  Bilirubin ≤1.5 X upper limit of normal (ULN) or ≤3 X ULN for patients with&#xD;
                  Gilbert's disease,&#xD;
&#xD;
               -  Serum creatinine ≤1.5 X ULN,&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 X ULN;&#xD;
&#xD;
         14. Women of childbearing potential (WOCBP): Premenopausal females who had at least one&#xD;
             menstrual cycle in the past 12 months and capable to become pregnant. They must have a&#xD;
             negative serum beta-HCG pregnancy test result within seven days from start of&#xD;
             treatment;&#xD;
&#xD;
         15. Women of childbearing potential and all men (and their female partners of childbearing&#xD;
             potential) who are sexually active must agree to use adequate method of contraception&#xD;
             at study entry, during treatment and for at least 9 months (270 days) following the&#xD;
             last dose of study drug;&#xD;
&#xD;
         16. Signed informed consent form prior to any protocol-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following exclusion criteria will not be eligible to&#xD;
        participate in the study:&#xD;
&#xD;
          1. Patients with evidence of large cell transformation (LCT) based on central histologic&#xD;
             evaluation at screening;&#xD;
&#xD;
          2. Receipt of live vaccines within 4 weeks prior to treatment;&#xD;
&#xD;
          3. Central nervous system (CNS) lymphoma involvement;&#xD;
&#xD;
          4. Prior administration of IPH4102;&#xD;
&#xD;
          5. Concurrent enrollment in another clinical trial, unless it is an observational (non -&#xD;
             interventional) clinical study or the follow-up period of an interventional study;&#xD;
&#xD;
          6. Autologous stem cell transplantation less than 3 months prior to enrollment;&#xD;
&#xD;
          7. Prior allogenic transplantation;&#xD;
&#xD;
          8. Patients who have undergone major surgery ≤ 4 weeks prior to study entry;&#xD;
&#xD;
          9. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral,&#xD;
             bacterial, or fungal infection;&#xD;
&#xD;
         10. Patients who have active Hepatitis B or C virus infection;&#xD;
&#xD;
         11. Known or tested positive for human immunodeficiency virus (HIV);&#xD;
&#xD;
         12. Patients with a history of other malignancies during the past five years apart from&#xD;
             the disease subject of this study. The following are exempt from the five-year limit:&#xD;
             non-melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer,&#xD;
             biopsy-proven cervical intraepithelial neoplasia, Ductal carcinoma in situ (DCIS) or&#xD;
             cervical carcinoma in situ;&#xD;
&#xD;
         13. Pregnant or breastfeeding women;&#xD;
&#xD;
         14. Patients with congestive heart failure, Class III or IV, by New York Heart Association&#xD;
             (NYHA) criteria;&#xD;
&#xD;
         15. Patients with autoimmune disease on systemic immunosuppressive treatment;&#xD;
&#xD;
         16. Patients with any serious underlying medical condition that would impair their ability&#xD;
             to receive or tolerate the planned treatment and/or comply with study protocol;&#xD;
&#xD;
         17. Patients with dementia or altered mental status that would preclude understanding and&#xD;
             rendering of informed consent document.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Innate Pharma</last_name>
    <phone>+33484903084</phone>
    <email>clinical.trials@innate-pharma.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amitkumar MEHTA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA) - Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert ERADAT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youn H KIM, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lubomir SOKOL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia SEMINARIO-VIDAL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric JACOBSEN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130-4899</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha MEHTA-SHAH, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick LANSIGAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universal Dermatology, PLLC68</name>
      <address>
        <city>Fairport</city>
        <state>New York</state>
        <zip>14450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian POLIGONE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Pediatric Neuromuscular Center Columbia UMC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larisa GESKIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen J KIM, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierluigi PORCU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg AKILOV, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auris HUEN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Health Care Services</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer DeSIMONE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie BEYLOT-BARRY, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saskia ORO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MORTIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane DALLE, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Marc SCHIANO de COLELLA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier DEREURE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis Service de Dermatologie</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine BAGOT, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle-CHU de Rouen Clinique Dermatologie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Bénédicte DUVLA-MODESTE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud Département de Dermatologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge BOULINGUEZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours, Hôpital Trousseau, service Dermatologie</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MACHET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatology, Ruhr-University Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René STRANZENBACH, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose MORITZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike WEHKAMP, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf STADLER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia Lorenzo e Ariosto Seragnoli</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pier Luigi ZINZANI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessendra TUCCI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Dermopatico dell'Immacolata (IDI-IRCCS)</name>
      <address>
        <city>Roma</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessendro MONOPOLI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo FAVA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea COMBALIA-ESCUDERO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando GALLARDO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo ORTIZ-ROMERO, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Consepcion ROMAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael BOTELLA ESTRADA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorci Hospital General Universitari de Valencia Servicio de Dermatología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amparo PEREZ-FERRIOLS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK - Christie Hospital Foundation NHS Trust - Dept of Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

